Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokineticsSBS-147 is a novel and potent oral ...

Sparian Biosciences has initiated a Phase I study of SBS-147, an arylepoxamide receptor (AEAr) agonist under development for ...

Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety ...

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate pain ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...

– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – – Treatment with VX-993 was generally safe and well tolerated, with ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

Credit: Getty Images Researchers assessed the safety and efficacy of suzetrigine, a non-opioid pain signal inhibitor, on moderate to severe acute pain from in patients with surgical and nonsurgical ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled ...